{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:02:00Z","timestamp":1789682520761,"version":"4.0.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"MOST | National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["#82404066"],"award-info":[{"award-number":["#82404066"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"MOST | National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["#82172889"],"award-info":[{"award-number":["#82172889"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"MOST | National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["#82173012"],"award-info":[{"award-number":["#82173012"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"JST | Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["#BK20241139"],"award-info":[{"award-number":["#BK20241139"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"crossref","award":["#320030-231251"],"award-info":[{"award-number":["#320030-231251"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"published-print":{"date-parts":[[2025,9,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Pleural mesothelioma (PM) is one of the deadliest cancers, with limited therapeutic options due to its therapeutically intractable genome, which is characterized by the functional inactivation of tumor suppressor genes (TSGs) and high tumor heterogeneity, including diverse metabolic adaptations. However, the molecular mechanisms underlying these metabolic alterations remain poorly understood, particularly how TSG inactivation rewires tumor metabolism to drive tumorigenesis and create metabolic dependencies. Through integrated multi-omics analysis, we identify for the first time that\n                    <jats:italic>NF2<\/jats:italic>\n                    loss of function defines a distinct PM subtype characterized by enhanced de novo pyrimidine synthesis, which\n                    <jats:italic>NF2<\/jats:italic>\n                    -deficient PM cells are critically dependent on for sustained proliferation in vitro and in vivo. Mechanistically,\n                    <jats:italic>NF2<\/jats:italic>\n                    loss activates YAP, a downstream proto-oncogenic transcriptional coactivator in the Hippo signalling pathway, which in turn upregulates\n                    <jats:italic>CAD<\/jats:italic>\n                    and\n                    <jats:italic>DHODH<\/jats:italic>\n                    , key enzymes in the de novo pyrimidine biosynthesis pathway. Our findings provide novel insights into metabolic reprogramming in PM, revealing de novo pyrimidine synthesis as a synthetic lethal vulnerability in\n                    <jats:italic>NF2<\/jats:italic>\n                    -deficient tumors. This work highlights a potential therapeutic strategy for targeting\n                    <jats:italic>NF2<\/jats:italic>\n                    -deficient mesothelioma through metabolic intervention.\n                  <\/jats:p>","DOI":"10.1038\/s44321-025-00278-4","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T13:21:51Z","timestamp":1753363311000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["De novo pyrimidine synthesis is a collateral metabolic vulnerability in NF2-deficient mesothelioma"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4691-1761","authenticated-orcid":false,"given":"Duo","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengchen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyuan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6823-313X","authenticated-orcid":false,"given":"Haibin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs","family":"Heged\u00fcs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M","family":"Marti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Dorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4664-6029","authenticated-orcid":false,"given":"Shun-Qing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0699-079X","authenticated-orcid":false,"given":"Ralph A","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1199-6520","authenticated-orcid":false,"given":"Ren-Wang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9941-0634","authenticated-orcid":false,"given":"Yongqian","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"278_CR1","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/mc.23497","volume":"62","author":"G Adhikary","year":"2023","unstructured":"Adhikary G, Shrestha S, Naselsky W, Newland JJ, Chen X, Xu W, Emadi A, Friedberg JS, Eckert RL (2023) Mesothelioma cancer cells are glutamine addicted and glutamine restriction reduces YAP1 signaling to attenuate tumor formation. Mol Carcinog 62:438\u2013449","journal-title":"Mol Carcinog"},{"key":"278_CR2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cmet.2018.10.014","volume":"29","author":"M Bajzikova","year":"2019","unstructured":"Bajzikova M, Kovarova J, Coelho AR, Boukalova S, Oh S, Rohlenova K, Svec D, Hubackova S, Endaya B, Judasova K et al (2019) Reactivation of dihydroorotate dehydrogenase-driven pyrimidine biosynthesis restores tumor growth of respiration-deficient cancer cells. Cell Metab 29:399\u2013416.e10","journal-title":"Cell Metab"},{"key":"278_CR3","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0140-6736(20)30164-1","volume":"395","author":"PL Bedard","year":"2020","unstructured":"Bedard PL, Hyman DM, Davids MS, Siu LL (2020) Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet 395:1078\u20131088","journal-title":"Lancet"},{"key":"278_CR4","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-09307-6","volume":"10","author":"Y Blum","year":"2019","unstructured":"Blum Y, Meiller C, Quetel L, Elarouci N, Ayadi M, Tashtanbaeva D, Armenoult L, Montagne F, Tranchant R, Renier A et al (2019) Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nat Commun 10:1333","journal-title":"Nat Commun"},{"key":"278_CR5","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, Gnad F, Nguyen TT, Jaiswal BS, Chirieac LR et al (2016) Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet 48:407\u2013416","journal-title":"Nat Genet"},{"key":"278_CR6","first-page":"402","volume":"69","author":"M Carbone","year":"2019","unstructured":"Carbone M, Adusumilli PS, Alexander JrHR, Baas P, Bardelli F, Bononi A, Bueno R, Felley-Bosco E, Galateau-Salle F, Jablons D et al (2019) Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin 69:402\u2013429","journal-title":"CA Cancer J Clin"},{"key":"278_CR7","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/(SICI)1098-2264(199903)24:3<238::AID-GCC9>3.0.CO;2-M","volume":"24","author":"JQ Cheng","year":"1999","unstructured":"Cheng JQ, Lee WC, Klein MA, Cheng GZ, Jhanwar SC, Testa JR (1999) Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation. Genes Chromosomes Cancer 24:238\u2013242","journal-title":"Genes Chromosomes Cancer"},{"key":"278_CR8","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/cdd.2015.165","volume":"23","author":"T Chernova","year":"2016","unstructured":"Chernova T, Sun XM, Powley IR, Galavotti S, Grosso S, Murphy FA, Miles GJ, Cresswell L, Antonov AV, Bennett J et al (2016) Molecular profiling reveals primary mesothelioma cell lines recapitulate human disease. Cell Death Differ 23:1152\u20131164","journal-title":"Cell Death Differ"},{"key":"278_CR9","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/ncb3389","volume":"18","author":"AG Cox","year":"2016","unstructured":"Cox AG, Hwang KL, Brown KK, Evason K, Beltz S, Tsomides A, O\u2019Connor K, Galli GG, Yimlamai D, Chhangawala S et al (2016) Yap reprograms glutamine metabolism to increase nucleotide biosynthesis and enable liver growth. Nat Cell Biol 18:886\u2013896","journal-title":"Nat Cell Biol"},{"key":"278_CR10","unstructured":"Crispi S, Calogero RA, Santini M, Mellone P, Vincenzi B, Citro G, Vicidomini G, Fasano S, Meccariello R, Cobellis G et al (2009) Gene Expression Omnibus GSE12345 (https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE12345). [DATASET]"},{"key":"278_CR11","unstructured":"De Rienzo A, Coleman MH, Yeap BY, Severson DT, Wadowski B, Gustafson CE, Jensen RV, Chirieac LR, Richards WG, Bueno R (2021) Gene Expression Omnibus GSE163720 (https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE163720). [DATASET]"},{"key":"278_CR12","unstructured":"De Rienzo A, Richards WG, Yeap BY, Coleman MH, Sugarbaker PE, Chirieac LR, Wang YE, Quackenbush J, Jensen RV, Bueno R (2013) Gene Expression Omnibus GSE42977 (https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE42977). [DATASET]"},{"key":"278_CR13","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41573-020-0070-z","volume":"19","author":"A Dey","year":"2020","unstructured":"Dey A, Varelas X, Guan K-L (2020) Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat Rev Drug Discov 19:480\u2013494","journal-title":"Nat Rev Drug Discov"},{"key":"278_CR14","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1158\/2159-8290.CD-20-1211","volume":"11","author":"P Dey","year":"2021","unstructured":"Dey P, Kimmelman AC, DePinho RA (2021) Metabolic Codependencies in the Tumor Microenvironment. Cancer Discov 11:1067\u20131081","journal-title":"Cancer Discov"},{"key":"278_CR15","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/s41590-024-01867-0","volume":"25","author":"V Dotsenko","year":"2024","unstructured":"Dotsenko V, Tewes B, Hils M, Pasternack R, Isola J, Taavela J, Popp A, Sarin J, Huhtala H, Hiltunen P et al (2024) Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac disease. Nat Immunol 25:1218\u20131230","journal-title":"Nat Immunol"},{"key":"278_CR16","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.3390\/cancers13102347","volume":"13","author":"S Dulloo","year":"2021","unstructured":"Dulloo S, Bzura A, Fennell DA (2021) Precision therapy for mesothelioma: feasibility and new opportunities. Cancers 13:2347","journal-title":"Cancers"},{"key":"278_CR17","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41571-022-00649-7","volume":"19","author":"DA Fennell","year":"2022","unstructured":"Fennell DA, Dulloo S, Harber J (2022) Immunotherapy approaches for malignant pleural mesothelioma. Nat Rev Clin Oncol 19:573\u2013584","journal-title":"Nat Rev Clin Oncol"},{"key":"278_CR18","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1038\/sj.onc.1206593","volume":"22","author":"J Fleury-Feith","year":"2003","unstructured":"Fleury-Feith J, Lecomte C, Renier A, Matrat M, Kheuang L, Abramowski V, Levy F, Janin A, Giovannini M, Jaurand M-C (2003) Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours. Oncogene 22:3799\u20133805","journal-title":"Oncogene"},{"key":"278_CR19","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.celrep.2019.07.002","volume":"28","author":"S Fu","year":"2019","unstructured":"Fu S, Li Z, Xiao L, Hu W, Zhang L, Xie B, Zhou Q, He J, Qiu Y, Wen M et al (2019) Glutamine synthetase promotes radiation resistance via facilitating nucleotide metabolism and subsequent DNA damage repair. Cell Rep 28:1136\u20131143.e4","journal-title":"Cell Rep"},{"key":"278_CR20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cmet.2020.10.012","volume":"33","author":"Y Gong","year":"2021","unstructured":"Gong Y, Ji P, Yang YS, Xie S, Yu TJ, Xiao Y, Jin ML, Ma D, Guo LW, Pei YC et al (2021) Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets. Cell Metab 33:51\u201364.e9","journal-title":"Cell Metab"},{"key":"278_CR21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D (2022) Hallmarks of cancer: new dimensions. Cancer Discov 12:31\u201346","journal-title":"Cancer Discov"},{"key":"278_CR22","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann S, Castelo R, Guinney J (2013) GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinforma 14:7","journal-title":"BMC Bioinforma"},{"key":"278_CR23","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1158\/0008-5472.CAN-15-0291","volume":"75","author":"H Hayashi","year":"2015","unstructured":"Hayashi H, Higashi T, Yokoyama N, Kaida T, Sakamoto K, Fukushima Y, Ishimoto T, Kuroki H, Nitta H, Hashimoto D et al (2015) An imbalance in TAZ and YAP expression in hepatocellular carcinoma confers cancer stem cell-like behaviors contributing to disease progression. Cancer Res 75:4985\u20134997","journal-title":"Cancer Res"},{"key":"278_CR24","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.lungcan.2023.03.003","volume":"178","author":"L Heged\u00fcs","year":"2023","unstructured":"Heged\u00fcs L, Okumus \u00d6, Mairinger F, Ploenes T, Reuter S, Schuler M, Welt A, Vega-Rubin-de-Celis S, Theegarten D, Bankfalvi A et al (2023) TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy. Lung Cancer 178:237\u2013246","journal-title":"Lung Cancer"},{"key":"278_CR25","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","volume":"8","author":"J Hmeljak","year":"2018","unstructured":"Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA et al (2018) Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov 8:1548\u20131565","journal-title":"Cancer Discov"},{"key":"278_CR26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41573-019-0046-z","volume":"19","author":"A Huang","year":"2020","unstructured":"Huang A, Garraway LA, Ashworth A, Weber B (2020) Synthetic lethality as an engine for cancer drug target discovery. Nat Rev Drug Discov 19:23\u201338","journal-title":"Nat Rev Drug Discov"},{"key":"278_CR27","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","volume":"33","author":"A Ianevski","year":"2017","unstructured":"Ianevski A, He L, Aittokallio T, Tang J (2017) SynergyFinder: a web application for analyzing drug combination dose-response matrix data. Bioinformatics 33:2413\u20132415","journal-title":"Bioinformatics"},{"key":"278_CR28","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMra1912719","volume":"385","author":"SM Janes","year":"2021","unstructured":"Janes SM, Alrifai D, Fennell DA (2021) Perspectives on the treatment of malignant pleural mesothelioma. N Engl J Med 385:1207\u20131218","journal-title":"N Engl J Med"},{"key":"278_CR29","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3390\/cancers15020546","volume":"15","author":"M Jiang","year":"2023","unstructured":"Jiang M, Song Y, Liu H, Jin Y, Li R, Zhu X (2023) DHODH inhibition exerts synergistic therapeutic effect with cisplatin to induce ferroptosis in cervical cancer through regulating mTOR pathway. Cancers 15:546","journal-title":"Cancers"},{"key":"278_CR30","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ccr.2008.01.030","volume":"13","author":"J Jongsma","year":"2008","unstructured":"Jongsma J, van Montfort E, Vooijs M, Zevenhoven J, Krimpenfort P, van der Valk M, van de Vijver M, Berns A (2008) A conditional mouse model for malignant mesothelioma. Cancer Cell 13:261\u2013271","journal-title":"Cancer Cell"},{"key":"278_CR31","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.cmet.2019.08.013","volume":"30","author":"J Kim","year":"2019","unstructured":"Kim J, DeBerardinis RJ (2019) Mechanisms and implications of metabolic heterogeneity in cancer. Cell Metab 30:434\u2013446","journal-title":"Cell Metab"},{"key":"278_CR32","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbapap.2021.140623","volume":"1869","author":"GP Lanfredi","year":"2021","unstructured":"Lanfredi GP, Thome CH, Ferreira GA, Silvestrini VC, Masson AP, Vargas AP, Grassi ML, Poersch A, Candido Dos Reis FJ, Faca VM (2021) Analysis of ovarian cancer cell secretome during epithelial to mesenchymal transition reveals a protein signature associated with advanced stages of ovarian tumors. Biochim Biophys Acta Proteins Proteom 1869:140623","journal-title":"Biochim Biophys Acta Proteins Proteom"},{"key":"278_CR33","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/bioinformatics\/bts034","volume":"28","author":"JT Leek","year":"2012","unstructured":"Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD (2012) The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28:882\u2013883","journal-title":"Bioinformatics"},{"key":"278_CR34","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.ajpath.2019.04.007","volume":"189","author":"M Li","year":"2019","unstructured":"Li M, Wang L, Zhan Y, Zeng T, Zhang X, Guan XY, Li Y (2019) Membrane Metalloendopeptidase (MME) suppresses metastasis of esophageal squamous cell carcinoma (ESCC) by inhibiting FAK-RhoA signaling axis. Am J Pathol 189:1462\u20131472","journal-title":"Am J Pathol"},{"key":"278_CR35","volume":"6","author":"SQ Liang","year":"2015","unstructured":"Liang SQ, Marti TM, Dorn P, Froment L, Hall SR, Berezowska S, Kocher G, Schmid RA, Peng RW (2015) Blocking the epithelial-to-mesenchymal transition pathway abrogates resistance to anti-folate chemotherapy in lung cancer. Cell Death Dis 6:e1824","journal-title":"Cell Death Dis"},{"key":"278_CR36","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jmcb\/mjy070","volume":"11","author":"J Liu","year":"2019","unstructured":"Liu J, Zhang C, Hu W, Feng Z (2019) Tumor suppressor p53 and metabolism. J Mol Cell Biol 11:284\u2013292","journal-title":"J Mol Cell Biol"},{"key":"278_CR37","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41588-023-01321-1","volume":"55","author":"L Mangiante","year":"2023","unstructured":"Mangiante L, Alcala N, Sexton-Oates A, Di Genova A, Gonzalez-Perez A, Khandekar A, Bergstrom EN, Kim J, Liu X, Blazquez-Encinas R et al (2023) Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity. Nat Genet 55:607\u2013618","journal-title":"Nat Genet"},{"key":"278_CR38","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41586-021-03539-7","volume":"593","author":"C Mao","year":"2021","unstructured":"Mao C, Liu X, Zhang Y, Lei G, Yan Y, Lee H, Koppula P, Wu S, Zhuang L, Fang B et al (2021) DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature 593:586\u2013590","journal-title":"Nature"},{"key":"278_CR39","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013631","volume":"14","author":"A Marazioti","year":"2022","unstructured":"Marazioti A, Krontira AC, Behrend SJ, Giotopoulou GA, Ntaliarda G, Blanquart C, Bayram H, Iliopoulou M, Vreka M, Trassl L et al (2022) KRAS signaling in malignant pleural mesothelioma. EMBO Mol Med 14:e13631","journal-title":"EMBO Mol Med"},{"key":"278_CR40","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-021-00931-w","volume":"13","author":"C Meiller","year":"2021","unstructured":"Meiller C, Montagne F, Hirsch TZ, Caruso S, de Wolf J, Bayard Q, Assie JB, Meunier L, Blum Y, Quetel L et al (2021) Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma. Genome Med 13:113","journal-title":"Genome Med"},{"key":"278_CR41","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41568-023-00557-7","volume":"23","author":"NJ Mullen","year":"2023","unstructured":"Mullen NJ, Singh PK (2023) Nucleotide metabolism: a pan-cancer metabolic dependency. Nat Rev Cancer 23:275\u2013294","journal-title":"Nat Rev Cancer"},{"key":"278_CR42","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.15252\/embr.201643030","volume":"17","author":"R Nagel","year":"2016","unstructured":"Nagel R, Semenova EA, Berns A (2016) Drugging the addict: non-oncogene addiction as a target for cancer therapy. EMBO Rep 17:1516\u20131531","journal-title":"EMBO Rep"},{"key":"278_CR43","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/sj.bjc.6690650","volume":"81","author":"Y Ohta","year":"1999","unstructured":"Ohta Y, Shridhar V, Bright RK, Kalemkerian GP, Du W, Carbone M, Watanabe Y, Pass HI (1999) VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 81:54\u201361","journal-title":"Br J Cancer"},{"key":"278_CR44","doi-asserted-by":"crossref","first-page":"5618","DOI":"10.1158\/0008-5472.CAN-13-0964","volume":"73","author":"L Ostergaard","year":"2013","unstructured":"Ostergaard L, Tietze A, Nielsen T, Drasbek KR, Mouridsen K, Jespersen SN, Horsman MR (2013) The relationship between tumor blood flow, angiogenesis, tumor hypoxia, and aerobic glycolysis. Cancer Res 73:5618\u20135624","journal-title":"Cancer Res"},{"key":"278_CR45","volume":"4","author":"GK Pandey","year":"2023","unstructured":"Pandey GK, Landman N, Neikes HK, Hulsman D, Lieftink C, Beijersbergen R, Kolluri KK, Janes SM, Vermeulen M, Badhai J et al (2023) Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma. Cell Rep Med 4:100915","journal-title":"Cell Rep Med"},{"key":"278_CR46","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/1878-0261.12651","volume":"14","author":"L Quetel","year":"2020","unstructured":"Quetel L, Meiller C, Assie JB, Blum Y, Imbeaud S, Montagne F, Tranchant R, de Wolf J, Caruso S, Copin MC et al (2020) Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival. Mol Oncol 14:1207\u20131223","journal-title":"Mol Oncol"},{"key":"278_CR47","unstructured":"Roe OD, Szulkin A, Anderssen E, Flatberg A, Sandeck H, Amundsen T, Erlandsen SE, Dobra K, Sundstrom SH (2012) European Bioinformatics Institute E-MTAB-1109 (https:\/\/www.ebi.ac.uk\/biostudies\/ArrayExpress\/studies\/E-MTAB-1109?query=E-MTAB-1109). [DATASET]"},{"key":"278_CR48","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1016\/j.cell.2024.05.039","volume":"187","author":"SR Savage","year":"2024","unstructured":"Savage SR, Yi X, Lei JT, Wen B, Zhao H, Liao Y, Jaehnig EJ, Somes LK, Shafer PW, Lee TD et al (2024) Pan-cancer proteogenomics expands the landscape of therapeutic targets. Cell 187:4389\u20134407.e15","journal-title":"Cell"},{"key":"278_CR49","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-022-01646-1","volume":"21","author":"H Schinke","year":"2022","unstructured":"Schinke H, Shi E, Lin Z, Quadt T, Kranz G, Zhou J, Wang H, Hess J, Heuer S, Belka C et al (2022) A transcriptomic map of EGFR-induced epithelial-to-mesenchymal transition identifies prognostic and therapeutic targets for head and neck cancer. Mol Cancer 21:178","journal-title":"Mol Cancer"},{"key":"278_CR50","doi-asserted-by":"crossref","DOI":"10.3389\/ftox.2023.1161995","volume":"5","author":"Y Sekido","year":"2023","unstructured":"Sekido Y, Sato T (2023) NF2 alteration in mesothelioma. Front Toxicol 5:1161995","journal-title":"Front Toxicol"},{"key":"278_CR51","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ccell.2022.07.011","volume":"40","author":"DD Shi","year":"2022","unstructured":"Shi DD, Savani MR, Levitt MM, Wang AC, Endress JE, Bird CE, Buehler J, Stopka SA, Regan MS, Lin YF et al (2022) De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma. Cancer Cell 40:939\u2013956.e16","journal-title":"Cancer Cell"},{"key":"278_CR52","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s42255-023-00774-2","volume":"5","author":"OS Skinner","year":"2023","unstructured":"Skinner OS, Blanco-Fernandez J, Goodman RP, Kawakami A, Shen H, Kemeny LV, Joesch-Cohen L, Rees MG, Roth JA, Fisher DE et al (2023) Salvage of ribose from uridine or RNA supports glycolysis in nutrient-limited conditions. Nat Metab 5:765\u2013776","journal-title":"Nat Metab"},{"key":"278_CR53","doi-asserted-by":"crossref","first-page":"5026","DOI":"10.1158\/0008-5472.CAN-16-2834","volume":"77","author":"DS Stepanova","year":"2017","unstructured":"Stepanova DS, Semenova G, Kuo Y-M, Andrews AJ, Ammoun S, Hanemann CO, Chernoff J (2017) An essential role for the tumor-suppressor merlin in regulating fatty acid synthesis. Cancer Res 77:5026\u20135038","journal-title":"Cancer Res"},{"key":"278_CR54","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41573-021-00339-6","volume":"21","author":"ZE Stine","year":"2022","unstructured":"Stine ZE, Schug ZT, Salvino JM, Dang CV (2022) Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov 21:141\u2013162","journal-title":"Nat Rev Drug Discov"},{"key":"278_CR55","unstructured":"Suraokar MB, Nunez MI, Diao L, Chow CW, Kim D, Behrens C, Lin H, Lee S, Raso G, Moran C et al (2014) Gene Expression Omnibus GSE51024 (https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE51024). [DATASET]"},{"key":"278_CR56","doi-asserted-by":"crossref","first-page":"53571","DOI":"10.18632\/oncotarget.10670","volume":"7","author":"F Teng","year":"2016","unstructured":"Teng F, Guo M, Liu F, Wang C, Dong J, Zhang L, Zou Y, Chen R, Sun K, Fu H et al (2016) Treatment with an SLC12A1 antagonist inhibits tumorigenesis in a subset of hepatocellular carcinomas. Oncotarget 7:53571\u201353582","journal-title":"Oncotarget"},{"key":"278_CR57","volume":"6","author":"H Tian","year":"2022","unstructured":"Tian H, Ni Z, Lam SM, Jiang W, Li F, Du J, Wang Y, Shui G (2022) Precise metabolomics reveals a diversity of aging-associated metabolic features. Small Methods 6:e2200130","journal-title":"Small Methods"},{"key":"278_CR58","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1073\/pnas.082099299","volume":"99","author":"R Tibshirani","year":"2002","unstructured":"Tibshirani R, Hastie T, Narasimhan B, Chu G (2002) Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 99:6567\u20136572","journal-title":"Proc Natl Acad Sci USA"},{"key":"278_CR59","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, Gill S, Harrington WF, Pantel S, Krill-Burger JM et al (2017) Defining a cancer dependency map. Cell 170:564\u2013576.e16","journal-title":"Cell"},{"key":"278_CR60","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41416-019-0661-9","volume":"122","author":"L Urso","year":"2020","unstructured":"Urso L, Cavallari I, Sharova E, Ciccarese F, Pasello G, Ciminale V (2020) Metabolic rewiring and redox alterations in malignant pleural mesothelioma. Br J Cancer 122:52\u201361","journal-title":"Br J Cancer"},{"key":"278_CR61","volume":"11","author":"W Wang","year":"2021","unstructured":"Wang W, Cui J, Ma H, Lu W, Huang J (2021) Targeting pyrimidine metabolism in the era of precision cancer medicine. Front Oncol 11:684961","journal-title":"Front Oncol"},{"key":"278_CR62","doi-asserted-by":"crossref","first-page":"eaau4972","DOI":"10.1126\/scitranslmed.aau4972","volume":"11","author":"X Wang","year":"2019","unstructured":"Wang X, Yang K, Wu Q, Kim LJY, Morton AR, Gimple RC, Prager BC, Shi Y, Zhou W, Bhargava S et al (2019) Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells. Sci Transl Med 11:eaau4972","journal-title":"Sci Transl Med"},{"key":"278_CR63","volume":"19","author":"Y Wang","year":"2018","unstructured":"Wang Y, Song F, Zhang B, Zhang L, Xu J, Kuang D, Li D, Choudhary MNK, Li Y, Hu M et al (2018) The 3D Genome Browser: a web-based browser for visualizing 3D genome organization and long-range chromatin interactions. Genome Biol 19:151","journal-title":"Genome Biol"},{"key":"278_CR64","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.devcel.2019.04.014","volume":"49","author":"SM White","year":"2019","unstructured":"White SM, Avantaggiati ML, Nemazanyy I, Di Poto C, Yang Y, Pende M, Gibney GT, Ressom HW, Field J, Atkins MB et al (2019) YAP\/TAZ inhibition induces metabolic and signaling rewiring resulting in targetable vulnerabilities in NF2-deficient tumor cells. Dev Cell 49:425\u2013443.e9","journal-title":"Dev Cell"},{"key":"278_CR65","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-022-01263-x","volume":"15","author":"HL Wu","year":"2022","unstructured":"Wu HL, Gong Y, Ji P, Xie YF, Jiang YZ, Liu GY (2022) Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy. J Hematol Oncol 15:45","journal-title":"J Hematol Oncol"},{"key":"278_CR66","volume":"5","author":"D Xu","year":"2024","unstructured":"Xu D, Gao Y, Yang H, Spils M, Marti TM, Losmanova T, Su M, Wang W, Zhou Q, Dorn P et al (2024) BAP1 deficiency inflames the tumor immune microenvironment and is a candidate biomarker for immunotherapy response in malignant pleural mesothelioma. JTO Clin Res Rep 5:100672","journal-title":"JTO Clin Res Rep"},{"key":"278_CR67","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1158\/1535-7163.MCT-19-0724","volume":"19","author":"D Xu","year":"2020","unstructured":"Xu D, Liang SQ, Yang H, Bruggmann R, Berezowska S, Yang Z, Marti TM, Hall SRR, Gao Y, Kocher GJ et al (2020) CRISPR screening identifies WEE1 as a combination target for standard chemotherapy in malignant pleural mesothelioma. Mol Cancer Ther 19:661\u2013672","journal-title":"Mol Cancer Ther"},{"key":"278_CR68","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41416-018-0145-3","volume":"119","author":"D Xu","year":"2018","unstructured":"Xu D, Liang SQ, Yang H, Luthi U, Riether C, Berezowska S, Marti TM, Hall SRR, Bruggmann R, Kocher GJ et al (2018) Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma. Br J Cancer 119:65\u201375","journal-title":"Br J Cancer"},{"key":"278_CR69","volume":"12","author":"D Xu","year":"2021","unstructured":"Xu D, Liang SQ, Yang Z, Yang H, Bruggmann R, Oberhaensli S, Berezowska S, Marti TM, Hall SRR, Dorn P et al (2021) Malignant pleural mesothelioma co-opts BCL-X(L) and autophagy to escape apoptosis. Cell Death Dis 12:406","journal-title":"Cell Death Dis"},{"key":"278_CR70","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/s41556-023-01146-4","volume":"25","author":"C Yang","year":"2023","unstructured":"Yang C, Zhao Y, Wang L, Guo Z, Ma L, Yang R, Wu Y, Li X, Niu J, Chu Q et al (2023) De novo pyrimidine biosynthetic complexes support cancer cell proliferation and ferroptosis defence. Nat Cell Biol 25:836\u2013847","journal-title":"Nat Cell Biol"},{"key":"278_CR71","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.3390\/cancers13071561","volume":"13","author":"H Yang","year":"2021","unstructured":"Yang H, Hall SRR, Sun B, Zhao L, Gao Y, Schmid RA, Tan ST, Peng RW, Yao F (2021) NF2 and canonical Hippo-YAP pathway define distinct tumor subsets characterized by different immune deficiency and treatment implications in human pleural mesothelioma. Cancers 13:1561","journal-title":"Cancers"},{"key":"278_CR72","volume":"12","author":"H Yang","year":"2020","unstructured":"Yang H, Xu D, Schmid RA, Peng RW (2020) Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma. Ther Adv Med Oncol 12:1758835920971421","journal-title":"Ther Adv Med Oncol"},{"key":"278_CR73","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40478-018-0524-2","volume":"6","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Ma C, Gearing M, Wang PG, Chin LS, Li L (2018) Integrated proteomics and network analysis identifies protein hubs and network alterations in Alzheimer\u2019s disease. Acta Neuropathol Commun 6:19","journal-title":"Acta Neuropathol Commun"},{"key":"278_CR74","doi-asserted-by":"crossref","first-page":"D729","DOI":"10.1093\/nar\/gky1094","volume":"47","author":"R Zheng","year":"2019","unstructured":"Zheng R, Wan C, Mei S, Qin Q, Wu Q, Sun H, Chen CH, Brown M, Zhang X, Meyer CA et al (2019) Cistrome Data Browser: expanded datasets and new tools for gene regulatory analysis. Nucleic Acids Res 47:D729\u2013D735","journal-title":"Nucleic Acids Res"},{"key":"278_CR75","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1021\/ac500472c","volume":"86","author":"M Zimmermann","year":"2014","unstructured":"Zimmermann M, Sauer U, Zamboni N (2014) Quantification and mass isotopomer profiling of alpha-keto acids in central carbon metabolism. Anal Chem 86:3232\u20133237","journal-title":"Anal Chem"}],"updated-by":[{"DOI":"10.1038\/s44321-025-00366-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000}}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-025-00278-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-025-00278-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-025-00278-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T10:28:01Z","timestamp":1786962481000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-025-00278-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":75,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,11]]}},"alternative-id":["278"],"URL":"https:\/\/doi.org\/10.1038\/s44321-025-00278-4","relation":{},"ISSN":["1757-4676","1757-4684"],"issn-type":[{"value":"1757-4676","type":"print"},{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"6 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s44321-025-00366-5","URL":"https:\/\/doi.org\/10.1038\/s44321-025-00366-5","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}],"article-number":"7"}}